2012/09-2016/06 B.S. Wuhan University Chemical biology
2016/09-2021/06 Ph.D. Peking University Integrated life science
2021/07-2023/08 Postdoc Peking University Chemical biology
2023/09 to present Associate Investigator Peking University Chemical biology
1. Bioorthogonal chemistry
Advancing bioorthogonal chemistry for innovative therapeutic applications.
2. Cancer immunotherapy
Harnessing chemical tools to develop next-generation immunotherapies, including multi-specific drugs, antibody conjugates, membrane protein degraders, and related modalities.
3. Prodrug therapy
Designing tumor-specific prodrugs to optimize the balance between safety and efficacy in chemo- and immuno-agents.
1. Lin F, Yin S, Zhang Z, et al. Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell. 2024, 187(26): 7470-7491.e32.
2. Zhang Y,# Zhang Z,# Lin F.* Multi-TACs: Targeting Solid Tumors with Multiple Immune Cell Co-engagers. ACS Chem Biol. 2025, 20(2): 245-247.
3. Lin F, Chen L, Zhang H, et al. Bioorthogonal Prodrug-Antibody Conjugates for On-Target and On-Demand Chemotherapy. CCS Chem. 2019, 1(2): 226-236.
4. Yao Q,# Lin F,# Lu C, et al. A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy. Bioconjugate Chem. 2023, 34(12), 2255-2262.
5. Chen P, Lin F, Lin J, Zhang H. Multi-specific bioconjugate linker and synthetic method therefor. Patent No: PCT/CN2021/130337, Granted: 2025-2-7.
6. Chen P, Zhang H, Han Y, Lin F, Lin J, Yang Y. Conjugate for target molecule modification and preparation method therefor. Patent No: PCT/CN2022/ 80594, Granted: 2023-3-31.
